Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 13/20 | 0.56 |
| ▸ | PGK1 | P00558 | 4/20 | 0.47 |
| ▸ | PGK2 | P07205 | 4/20 | 0.47 |
| ▸ | PTPN6 | P29350 | 7/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 5/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 5/20 | 0.41 |
| ▸ | PTPRC | P08575 | 5/20 | 0.40 |
| ▸ | PTPRB | P23467 | 3/20 | 0.40 |
| ▸ | CDC25A | P30304 | 1/20 | 0.40 |
| ▸ | PTPN22 | Q9Y2R2 | 2/20 | 0.40 |
| ▸ | EPM2A | O95278 | 1/20 | 0.40 |
| ▸ | CDC14A | Q9UNH5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5003956 | 0.89 | PTPN1 (0.67) | PTPN1PGK1PGK2PTPN6PTPN2 | |
| SCHEMBL7660739 | 0.89 | PGK1 (0.59) | PTPN1PGK1PGK2PTPN6PTPN2 | |
| SCHEMBL7591720 | 0.88 | PGK1 (0.57) | PTPN1PGK1PGK2PTPN6PTPN2 | |
| SCHEMBL7179732 | 0.88 | PTPN1 (0.69) | PTPN1PGK1PGK2PTPN6PTPN2 | |
| SCHEMBL7660736 | 0.76 | PGK1 (0.67) | PTPN1PGK1PGK2PTPN6PTPN2 | |
| SCHEMBL7179740 | 0.76 | PTPN1 (0.48) | PTPN1PGK1PGK2PTPN6PTPN2 | |
| SCHEMBL7183073 | 0.75 | PGK1 (0.40) | PTPN1PGK1PGK2PTPN6PTPN2 | |
| SCHEMBL7591715 | 0.75 | PGK1 (0.64) | PTPN1PGK1PGK2PTPN6PTPN2 | |
| SCHEMBL4316972 | 0.75 | PTPN1 (0.74) | PTPN1PGK1PGK2PTPN6PTPN2 | |
| SCHEMBL5003952 | 0.75 | PTPN1 (1.00) | PTPN1PGK1PGK2PTPN6PTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1268495-A1 | SULFUR SUBSTITUTED ARYLDIFLUOROMETHYLPHOSPHONIC ACIDS AS PTP-1B INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2003-01-02 | — | — | EP | claimed |
| US-6465444-B2 | PROTEIN TYROSINE PHOSPHATASES(PTP-1B); ANTIDIABETIC, ANTITUMOR AND ANOREXIGENIC AGENTS; COMBINATION THERAPY | MERCK FROSST CANADA & CO. | 2002-10-15 | — | — | US | claimed |
| US-20020002149-A1 | Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors | MERCK FROSST CANADA LTD. (CA) | 2002-01-03 | — | — | US | claimed |
| WO-2001070754-A1 | SULFUR SUBSTITUTED ARYLDIFLUOROMETHYLPHOSPHONIC ACIDS AS PTP-1B INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2001-09-27 | — | — | WO | claimed |
| EP-1268495-A1 | SULFUR SUBSTITUTED ARYLDIFLUOROMETHYLPHOSPHONIC ACIDS AS PTP-1B INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2003-01-02 | — | — | EP | disclosed |
| US-6465444-B2 | PROTEIN TYROSINE PHOSPHATASES(PTP-1B); ANTIDIABETIC, ANTITUMOR AND ANOREXIGENIC AGENTS; COMBINATION THERAPY | MERCK FROSST CANADA & CO. | 2002-10-15 | — | — | US | disclosed |
| US-20020002149-A1 | Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors | MERCK FROSST CANADA LTD. (CA) | 2002-01-03 | — | — | US | disclosed |
| WO-2001070754-A1 | SULFUR SUBSTITUTED ARYLDIFLUOROMETHYLPHOSPHONIC ACIDS AS PTP-1B INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002149-A1 | Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors | PTPRF, PTPRS, PTPRO | PTPN1 13/4885PGK1 615/4885PGK2 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.